logo-loader
viewUrigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain

Urigen Pharmaceuticals, Inc CEO Dan Vickery sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The privately-held company specializes in non-oncological urology treatments.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Etruscus Resources expecting busy field season as they look to expand...

Etruscus Resouces (CSE: ETR) CEO Gordon Lam joined Steve Darling from Proactive Vancouver with news the company is preparing to start their 2020 exploration season as they look to do work on both their Rock and Roll and Suger properties in the Golden Triangle of BC. Lam telling Proactive what...

21 minutes ago

2 min read